- Prev close
- $378.81
- Day range
- $372.63 – $379.90
- From 52-wk high
- -37.3%
- Next earnings
- in 72 days
ISRG’s +6.2% move is stock-specific rather than a broad-market effect, and it came with a strong intraday follow-through to $375.41. The underlying growth and margins are solid, but a 42.3 P/E and 30.6 forward P/E mean the setup is still sensitive to any change in procedure growth.
ISRG
INTUITIVE SURGICAL INC
As of Aug 4, 2026
66/100
Worth keeping an eye onHealth ScoreMove driver
The move looks stock-specific. ISRG closed at $375.41, up +6.2%, while the S&P 500 rose +1.8% and the Nasdaq 100 rose +3.4%; its peers were mixed, with ABT -1.5%, SYK -1.5%, BSX +1.4%, and EW +0.9%. That gap is too large to explain by the broad tape alone, so the primary driver is company-specific buying rather than a sector-wide rerating. The intraday path also matters: it opened at $361.755, traded up to $375.85, and closed at $375.41, which shows steady follow-through rather than a fade.
Volatility check
This looks like a meaningful but not abnormal move for a high-expectation name. ISRG’s TTM revenue growth is +20.7%, the latest quarter grew +18.5% YoY, and EPS is +21.8% YoY, with TTM gross margin at +66.7%, operating margin at +31.3%, and net margin at +28.4%. Those are strong fundamentals, but the valuation is also demanding at 42.3 P/E, 30.6 forward P/E, and 2.42 PEG — a PEG of 2.42 means investors are paying 2.42 times the growth rate, so good news can move the stock sharply, and so can any sign of slowing. Beta is 1.48, which supports above-market swings. The prior note in the facts says the stock declined when investors focused on slowing domestic procedure growth, so the market is still treating procedure trends as the key swing factor rather than the reported growth rates alone.
Earnings preview
The next earnings date is 2026-10-19. The facts do not give Street consensus for the upcoming quarter’s revenue, EPS, or margin targets, so I can’t quote an expected growth rate or margin profile for this print. What the market is likely to focus on, based on the recent commentary in the facts, is whether domestic procedure growth is re-accelerating, whether the company can keep revenue growth near the recent +18.5% YoY to +20.7% TTM range, and whether margins stay near the current +66.7% gross, +31.3% operating, and +28.4% net levels. The only prior reaction clue in the facts is that the stock declined after a Q2 2026 beat because investors focused on slowing domestic procedure growth, so procedure momentum is the key variable to watch again.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track ISRG with WhyIHold
Get a plain-English explanation the next time INTUITIVE SURGICAL INC makes a big move — so you know whether it's benign or worth your attention.